VINC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VINC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Vincerx Pharma's total inventories for the quarter that ended in Dec. 2024 was $0.00 Mil. Vincerx Pharma's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was $0.00 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Vincerx Pharma's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $-0.13.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Vincerx Pharma's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vincerx Pharma Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Total Inventories | Get a 7-Day Free Trial | - | - | - | - | - |
Vincerx Pharma Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Total Inventories | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Vincerx Pharma (NAS:VINC) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Vincerx Pharma's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is
Net-Net Working Capital Per Share (Q: Dec. 2024 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (4.987 | + | 0.75 * 0 | + | 0.5 * 0 | - | 5.281 |
- | 0 | - | 0) | / | 2.240 | ||
= | -0.13 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Vincerx Pharma's Days Inventory for the three months ended in Dec. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Dec. 2024 ) | / | Cost of Goods Sold (Q: Dec. 2024 ) | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Vincerx Pharma's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Dec. 2024 ) | / | Average Total Inventories (Q: Dec. 2024 ) |
= | 0 | / | 0 | |
= | N/A |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Vincerx Pharma's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | 0 | / | 0 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Vincerx Pharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexander A. Seelenberger | officer: Chief Financial Officer | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
Raquel E. Izumi | director, 10 percent owner, officer: Chief Operations Officer | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
Ahmed Md Hamdy | director, 10 percent owner, officer: President and CEO | 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Tom C Thomas | officer: See Remarks | 180 LOMA ALTRO, C/O MOCON INC, LOS GATOS CA 95030 |
Christopher P. Lowe | director | 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258 |
Laura I. Bushnell | director | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
Rubric Capital Management Lp | 10 percent owner | 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017 |
David Efraim Rosen | 10 percent owner | 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017 |
Sooin Hwang | officer: Chief Business Officer | 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306 |
Xiaoming Zhang | officer: Chief Technology Officer | 260 SHERIDAN AVE, SUITE 400, PALO ALTO CA 94306 |
Ruth E. Stevens | director | 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306 |
Garban Hermes De Jesus | officer: Chief Medical Officer | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
John C. Byrd | 10 percent owner | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
Brian Druker | director | ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
John H. Lee | director | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
From GuruFocus
By GlobeNewswire • 01-07-2024
By Marketwired • 01-02-2025
By Marketwired • 04-25-2024
By Marketwired • 05-14-2024
By GuruFocus Research • 03-29-2024
By Marketwired • 11-02-2023
By GuruFocus News • 11-15-2024
By Marketwired • 09-19-2023
By Marketwired • 09-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.